Case Report

Reversal of pure red cell aplasia by varicella zoster virus infection

Al-Anazi KA*, Kanfar S, Aldayel A, Abduljalil O and Sayyed AH

Published: 03 May, 2019 | Volume 3 - Issue 1 | Pages: 001-010

Background: Pure red cell aplasia is characterized by anemia, reticulocytopenia and diminished bone marrow erythroid precursors. It has multifactorial etiology and consequently several therapeutic interventions.

Case: In August 2017, a young patient was diagnosed to have pure red cell aplasia. She was given immunosuppressive therapy for approximately two months but this treatment was stopped due to intolerance. Later on she developed herpes zoster infection that was treated with valacyclovir. Subsequently, it was noted that the patient became blood transfusion independent due to normalization of her hemoglobin and regeneration of the erythroid precursors in the bone marrow.

Discussion: Varicella zoster virus behaves differently from other members of the herpes group of viruses such as cytomegalovirus and Epstein-Barr virus. Two retrospective studies, performed in patients with malignant hematological disorders and bone marrow failure, have shown that infection with the virus may cause stimulation of the three cell lines in the bone marrow and superior overall survival.

Conclusion: The outcome of the patient presented confirms the findings of the two studies showing long-term beneficial effects of varicella zoster virus infections in immunocompromised individuals.

Read Full Article HTML DOI: 10.29328/journal.jhcr.1001008 Cite this Article Read Full Article PDF


Pure red cell aplasia; Bone marrow; Blood transfusion; Immunosuppressive therapy; Varicella zoster virus


  1. Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008; 142: 505-514. Ref.: https://tinyurl.com/y24mg42v
  2. Means RT Jr. Pure red cell aplasia. Blood. 2016; 128: 2504- 2509. Ref.: https://tinyurl.com/y4wjzkf5
  3. Means RT Jr. Pure red cell aplasia. Hematology Am Soc Hematol Educ Program. 2016; 2016: 51-56. Ref.: https://tinyurl.com/y28ta36n
  4. Schrier SL. Acquired pure red cell aplasia in the adult. Edited by: Mentzer WC, Tirnauer JS. Up To Date. 2019; Ref.: https://tinyurl.com/y3facpmq
  5. Crabol Y, Terrier B, Rozenberg F, Pestre V, Legendre C, et al. Groupe d'experts de l'Assistance Publique-Hôpitaux de Paris. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013; 56: 968-977. Ref.: https://tinyurl.com/y65gru7m
  6. Ito T, Nakaya A, Fujita S, Satake A, Nakanishi T, et al. Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide. Leuk Res Rep. 2018; 10: 4-6. Ref.: https://tinyurl.com/y5r94vu7
  7. Sawlani KK, Chaudhary SC, Singh J, Raja DC, Mishra S, et al. Dapsone-induced pure red cell aplasia and cholestatic jaundice: A new experience for diagnosis and management. J Res Pharm Pract. 2016; 5: 215-218. Ref.: https://tinyurl.com/y3tt5dhh
  8. Liang TB, Li DL, Yu J, Bai XL, Liang L, et al. Pure red cell aplasia due to parvovirus B19 infection after liver transplantation: a case report and review of the literature. World J Gastroenterol. 2007; 13: 2007-2010. Ref.: https://tinyurl.com/y5rkl9bk
  9. Saito Y, Sawada Y, Koga Y, Sunaga N, Tsukagoshi Y, et al. Isoniazid-induced pure red cell aplasia in a patient with sarcoidosis: a patient summary and review of the literature. Intern Med. 2017; 56: 2753-2757. Ref.: https://tinyurl.com/y3852u2v
  10. Dutcher JP, Fan W, Wiernik PH. Pure red cell aplasia following interleukin-2 therapy. J Investig Med High Impact Case Rep. 2016; 4: 324709616643991. Ref.: https://tinyurl.com/y3zb2kcf
  11. Poudyal BS, Tuladhar S, Gyawali B. TKI-induced pure red cell aplasia: first case report of pure red cell aplasia with both imatinib and nilotinib. ESMO Open. 2016; 1: e000058. Ref.: https://tinyurl.com/y2ryzjug
  12. Luo Z, Xu N, Wang Y, Huang X, Cao C, et al. Linezolid-induced pure red cell aplasia: a case report and literature review. J Int Med Res. 2018; 46: 4837-4844. Ref.: https://tinyurl.com/y5hceksh
  13. Balikar R, Redkar NN, Patil MA, Pawar S. Myasthenia gravis and pure red cell aplasia: a rare association. BMJ Case Rep. 2013; 2013. pii: bcr2012008224. Ref.: https://tinyurl.com/y2y83xpa
  14. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004; 351: 1403-1408. Ref.: https://tinyurl.com/yxj9d332
  15. Sekiguchi Y, Shimada A, Imai H, Wakabayashi M, Sugimoto K, et al. A case of recurrent autoimmune hemolytic anemia during remission associated with acute pure red cell aplasia and hemophagocytic syndrome due to human parvovirus B19 infection successfully treated by steroid pulse therapy with a review of the literature. Int J Clin Exp Pathol. 2014; 7: 2624-2635. Ref.: https://tinyurl.com/y56ccbcn
  16. Balasubramanian SK, Sadaps M, Thota S, Aly M, Przychodzen BP, et al. Rational management approach to pure red cell aplasia. Haematologica. 2018; 103: 221-230. Ref.: https://tinyurl.com/yxlcmuq2
  17. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood. 2000; 96: 1184-1186. Ref.: https://tinyurl.com/y38xzcau
  18. Lipton JM, Ellis SR. Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am. 2009; 23: 261-282. Ref.: https://tinyurl.com/y5sc9kkj
  19. Vlachos A, Muir E. How I treat Diamond-Blackfan anemia. Blood. 2010; 116: 3715-3723. Ref.: https://tinyurl.com/yyd6tgrl
  20. Sjögren SE, Flygare J. Progress towards mechanism-based treatment for Diamond-Blackfan anemia. Sci World J. 2012; 2012: 184362. Ref.: https://tinyurl.com/y27amr3a
  21. Kawakami T, Sekiguchi N, Kobayashi J, Imi T, Matsuda K, et al. Frequent STAT3 mutations in CD8+ T cells from patients with pure red cell aplasia. Blood Adv. 2018; 2: 2704-2712. Ref.: https://tinyurl.com/y5pklsew
  22. Ishida F, Matsuda K, Sekiguchi N, Makishima H, Taira C, et al. STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci. 2014; 105: 342-346. Ref.: https://tinyurl.com/y6h3jdpu
  23. Qiu ZY, Fan L, Wang L, Qiao C, Wu YJ, et al. STAT3 mutations are frequent in T-cell large granular lymphocytic leukemia with pure red cell aplasia. J Hematol Oncol. 2013; 6: 82. Ref.: https://tinyurl.com/y2o894bn
  24. Savage SA, Dufour C. Classical inherited bone marrow failure syndromes with high risk for myelodysplastic syndrome and acute myelogenous leukemia. Semin Hematol. 2017; 54:105-114. Ref.: https://tinyurl.com/y2t7o8wb
  25. Kim HD, Kim KW, Park SY, Ko HJ, An YY, et al. Myelodysplastic syndrome with erythroid aplasia following pure red cell aplasia. Korean J Intern Med. 2004; 19: 193-195. Ref.: https://tinyurl.com/y67qpjhd
  26. Lipton JM, Federman N, Khabbaze Y, Schwartz CL, Hilliard LM, et al. Diamond-Black Anemia Registry. Osteogenic sarcoma associated with Diamond-Blackfan anemia: a report from the Diamond-Blackfan Anemia Registry. J Pediatr Hematol Oncol. 2001; 23: 39-44. Ref.: https://tinyurl.com/y3qqjznu
  27. Matsuda I, Tsuchida YA, Toyoshima F, Tozawa K, Ikehara H, et al. Occurrence of colon tumors in a 16-year-old Japanese boy after hematopoietic stem cell transplantation for Diamond Blackfan anemia at age of 4: a case report. Int J Clin Exp Pathol. 2015; 8: 5938-5943. Ref.: https://tinyurl.com/yxrpq7az
  28. Bannon SA, DiNardo CD. Hereditary predispositions to myelodysplastic syndrome. Int J Mol Sci. 2016; 17. pii: E838. Ref.: https://tinyurl.com/y27ucy5o
  29. Garewal G, Ahluwalia J, Das R, Marwaha RK. Parvovirus B19associated transient red cell aplasia in children: the role of bone marrow examination in unusual presentations. Pediatr Hematol Oncol. 2004; 21: 505-511. Ref.: https://tinyurl.com/yyk3bjl6
  30. Lin CS, Yu YB, Hsu HS, Chou TY, Hsu WH, et al. Pure red cell aplasia and hypogammaglobulinemia in a patient with thymoma. J Chin Med Assoc. 2009; 72: 34-38. Ref.: https://tinyurl.com/y2lnnq7b
  31. Kanellopoulos A, Koutsi K, Georgiou G, Ntalagiorgos T, Petevi K, et al. Pure red cell aplasia complicating the course of long-standing mantle cell lymphoma. Int J Hematol. 2014; 99: 777-781. Ref.: https://tinyurl.com/yxjr6ayz
  32. Morinet F, Leruez-Ville M, Pillet S, Fichelson S. Concise review: Anemia caused by viruses. Stem Cells. 2011; 29: 1656-1660. Ref.: https://tinyurl.com/y4f4samu
  33. Au WY, Lam CC, Chim CS, Pang AW, Kwong YL. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk Res. 2005; 29: 1213-1215. Ref.: https://tinyurl.com/yyafyq7l
  34. He GS, Zhang X, Wu DP, Sun AN, Miao M, et al. Retreatment with fludarabine and cyclosporine for one case of refractory pure red cell aplasia. Chin Med Sci J. 2008; 23: 60-62. Ref.: https://tinyurl.com/y6yfm9p3
  35. Messner HA, Fauser AA, Curtis JE, Dotten D. Control of antibody-mediated pure red-cell aplasia by plasmapheresis. N Engl J Med. 1981; 304: 1334-1338. Ref.: https://tinyurl.com/y57dlb8g
  36. Palmieri G, Lastoria S, Colao A, Vergara E, Varrella P, et al. Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone. N Engl J Med. 1997; 336: 263-265. Ref.: https://tinyurl.com/y4jb7nc5
  37. Eisemann G, Damesheq W. Splenectomy for pure red-cell hypoplastic (aregenerative) anemia associated with autoimmune hemolytic disease; report of a case. N Engl J Med. 1954; 251: 1044-1048. Ref.: https://tinyurl.com/yxql7g74
  38. McGuire WA, Yang HH, Bruno E, Brandt J, Briddell R, et al. Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. N Engl J Med. 1987; 317: 1004-1008. Ref.: https://tinyurl.com/y2rqt5l3
  39. Hirokawa M. Progress in the clinical management of pure red cell aplasia and future prospects. Rinsho Ketsueki. 2016; 57: 110-116. Ref.: https://tinyurl.com/y4hsjtwg
  40. Castelli R, Vismara A, Pavia G, Dagani R, Porro T. Relapsing pure red cell aplasia associated with B-cell chronic lymphocytic leukemia successfully treated by intravenous immunoglobulin concentrate. Ann Ital Med Int. 2002; 17: 47-50. Ref.: https://tinyurl.com/yxf34n22
  41. Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med. 1989; 321: 519-523. Ref.: https://tinyurl.com/y6lgcmkg
  42. Koduri PR, Kumapley R, Valladares J, Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin--a report of eight patients. Am J Hematol. 1999; 61: 16-20. Ref.: https://tinyurl.com/yxjxtjlp
  43. Hirokawa M, Sawada K, Fujishima N, Teramura M, Bessho M, et al. Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol. 2015; 169: 879-886. Ref.: https://tinyurl.com/y26e2mu5
  44. Kennedy PGE, Gershon AA. Clinical features of varicella-zoster virus infection. Viruses. 2018; 10. pii: E609. Ref.: https://tinyurl.com/y4tc4l38
  45. Weber DJ. Prevention and control of varicella-zoster virus in hospitals. Edited by: Hirsch MS, Mitty JM. Up To Date 2019. Ref.: https://tinyurl.com/yyp2jpre
  46. Cohrs RJ, Gilden DH, Mahalingam R. Varicella zoster virus latency, neurological disease and experimental models: an update. Front Biosci. 2004; 9: 751-762. Ref.: https://tinyurl.com/y6dwn4v4
  47. Albrecht MA, Levin MJ. Epidemiology, clinical manifestations and diagnosis of herpes zoster. Edited by: Hirsch MS, Mitty J. Up To Date. 2019; Ref.: https://tinyurl.com/y4l2cbfg
  48. Onozawa M, Hashino S, Takahata M, Fujisawa F, Kawamura T, et al. Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients. J Clin Microbiol. 2006; 44: 4441-4443. Ref.: https://tinyurl.com/yxu2vhkd
  49. Cvjetković D, Jovanović J, Hrnjaković-Cvjetković I, Brkić S, Bogdanović M. Reactivation of herpes zoster infection by varicellazoster virus. Med Pregl. 1999; 52: 125-128. Ref.: https://tinyurl.com/y6atj2b4
  50. Albrecht MA. Diagnosis of varicella zoster virus infection. Edited by: Hirsch MS, Mitty JM. Up To Date. 2019; Ref.: https://tinyurl.com/y4ykxdbw
  51. Erskine N, Tran H, Levin L, Ulbricht C, Fingeroth J, et al. A systematic review and meta-analysis on herpes zoster and the risk of cardiac and cerebrovascular events. PLoS One. 2017; 12: e0181565. Ref.: https://tinyurl.com/yxv3wtg2
  52. Breuer J, Whitley R. Varicella zoster virus: natural history and current therapies of varicella and herpes zoster. Herpes. 2007; 14 Suppl 2: 25-29. Ref.: https://tinyurl.com/y4293sbo
  53. Mustafa MB, Arduino PG, Porter SR. Varicella zoster virus: review of its management. J Oral Pathol Med. 2009; 38: 673-688. Ref.: https://tinyurl.com/y4cja5al
  54. Al-Anazi KA, Al-Jasser AM, Evans DA. Effect of varicella zoster virus infection on bone marrow function. Eur J Haematol. 2005; 75: 234-240. Ref.: https://tinyurl.com/y2c9rbum
  55. Kim SR, Khan F, Ramirez-Fort MK, Downing C, Tyring SK. Varicella zoster: an update on current treatment options and future perspectives. Expert Opin Pharmacother. 2014; 15: 61-71. Ref.: https://tinyurl.com/yxhzcekw
  56. Johnson RW. Herpes zoster in the immunocompetent patient: management of post-herpetic neuralgia. Herpes. 2003; 10: 38-45. Ref.: https://tinyurl.com/y6ezyjnx
  57. Wada-Shimosato Y, Tanoshima R, Hiratoko K, Takeuchi M, Tsujimoto SI, et al. Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Transpl Infect Dis. 2019; e13061. Ref.: https://tinyurl.com/yxom486h
  58. Wang L, Zhu L, Zhu H. Efficacy of varicella (VZV) vaccination: an update for the clinician. Ther Adv Vaccines. 2016; 4: 20-31. Ref.: https://tinyurl.com/y6jdwxqh
  59. Harada K, Heaton H, Chen J, Vazquez M, Meyer J. Zoster vaccine-associated primary varicella infection in an immunocompetent host. BMJ Case Rep. 2017; 2017. pii: bcr-2017-221166. Ref.: https://tinyurl.com/yywmryxu
  60. Gabutti G, Bonanni P, Conversano M, Fanelli G, Franco E, et al. Prevention of herpes zoster and its complications: from clinical evidence to real life experience. Hum Vaccin Immunother. 2017; 13: 391-398. Ref.: https://tinyurl.com/yxvd7ehv
  61. Belcaid Z, Lamfers ML, van Beusechem VW, Hoeben RC. Changing faces in virology: the Dutch shift from oncogenic to oncolytic viruses. Hum Gene Ther. 2014; 25: 875-884. Ref.: https://tinyurl.com/yywhme9z
  62. Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016 Oct; 107: 1373-1379. Ref.: https://tinyurl.com/y53r79zc
  63. Ajina A, Maher J. Prospects for combined use of oncolytic viruses and CAR T-cells. J Immunother Cancer. 2017; 5: 90. Ref.: https://tinyurl.com/y4gwuezv
  64. Howells A, Marelli G, Lemoine NR, Wang Y. Oncolytic virusesinteraction of virus and tumor cells in the battle to eliminate cancer. Front Oncol. 2017; 7: 195. Ref.: https://tinyurl.com/yykeu2ht
  65. Kamber C, Zimmerli S, Suter-Riniker F, Mueller BU, Taleghani BM, et al. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients. Bone Marrow Transplant. 2015; 50: 573-578. Ref.: https://tinyurl.com/yxuxmp7t


Figure 1

Figure 1

Figure 1

Figure 2

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More